Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction?

Francesco Montorsi, Alberto Briganti, Andrea Salonia, Patrizio Rigatti, Arthur Burnett

Research output: Contribution to journalArticle

Abstract

Introduction and objectives: To systematically analyze and review the available evidence about the potential role of chronic administration of phosphodiesterase type 5 (PDE-5) inhibitors for the cure of erectile dysfunction (ED) based on clinical and basic science data. Methods: Analysis of published full-length papers that were identified with Medline and Cancerlit from January 1993 to September 2005. Abstracts published in the journals European Urology, the Journal of Urology, the International Journal of Impotence Research, and the Journal of Sexual Medicine as official proceedings of internationally known scientific societies held in the same time period were also assessed. Results: Chronic administration of PDE-5 inhibitors have reportedly been associated with increased persistent vascular and endothelial function-which represents a key factor in maintaining vascular tone and inducing vasodilation-by increasing the level of endothelial cGMP generated by activation of endothelial nitric oxide. Clinical studies have revealed a potential protective role of these compounds on endothelial function in short- and long-term assessments. Several studies based on animal models have provided direct experimental support for the role of PDE-5 inhibitors in improving the structure and function of the cavernosal tissue and have suggested potential molecular mechanisms involved. Conclusions: Although evidence increasingly supports the potential role of chronic administration of PDE-5 inhibitors for improving erectile function in patients affected by ED, long-term data are lacking. However, data available from animal models support the evidence of potential benefits induced on endothelial function by chronic exposure to PDE-5 inhibitors.

Original languageEnglish (US)
Pages (from-to)979-986
Number of pages8
JournalEuropean Urology
Volume49
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

Phosphodiesterase 5 Inhibitors
Erectile Dysfunction
Urology
Blood Vessels
Animal Models
Vasodilation
Nitric Oxide
Medicine
Research

Keywords

  • Endothelial dysfunction
  • Erectile dysfunction
  • Phosphodiesterase type 5 inhibitors
  • Radical prostatectomy
  • Sildenafil
  • Tadalafil
  • Vardenafil

ASJC Scopus subject areas

  • Urology

Cite this

Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction? / Montorsi, Francesco; Briganti, Alberto; Salonia, Andrea; Rigatti, Patrizio; Burnett, Arthur.

In: European Urology, Vol. 49, No. 6, 06.2006, p. 979-986.

Research output: Contribution to journalArticle

Montorsi, Francesco ; Briganti, Alberto ; Salonia, Andrea ; Rigatti, Patrizio ; Burnett, Arthur. / Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction?. In: European Urology. 2006 ; Vol. 49, No. 6. pp. 979-986.
@article{6d20638fdb644f14b52da3ca6af542a5,
title = "Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction?",
abstract = "Introduction and objectives: To systematically analyze and review the available evidence about the potential role of chronic administration of phosphodiesterase type 5 (PDE-5) inhibitors for the cure of erectile dysfunction (ED) based on clinical and basic science data. Methods: Analysis of published full-length papers that were identified with Medline and Cancerlit from January 1993 to September 2005. Abstracts published in the journals European Urology, the Journal of Urology, the International Journal of Impotence Research, and the Journal of Sexual Medicine as official proceedings of internationally known scientific societies held in the same time period were also assessed. Results: Chronic administration of PDE-5 inhibitors have reportedly been associated with increased persistent vascular and endothelial function-which represents a key factor in maintaining vascular tone and inducing vasodilation-by increasing the level of endothelial cGMP generated by activation of endothelial nitric oxide. Clinical studies have revealed a potential protective role of these compounds on endothelial function in short- and long-term assessments. Several studies based on animal models have provided direct experimental support for the role of PDE-5 inhibitors in improving the structure and function of the cavernosal tissue and have suggested potential molecular mechanisms involved. Conclusions: Although evidence increasingly supports the potential role of chronic administration of PDE-5 inhibitors for improving erectile function in patients affected by ED, long-term data are lacking. However, data available from animal models support the evidence of potential benefits induced on endothelial function by chronic exposure to PDE-5 inhibitors.",
keywords = "Endothelial dysfunction, Erectile dysfunction, Phosphodiesterase type 5 inhibitors, Radical prostatectomy, Sildenafil, Tadalafil, Vardenafil",
author = "Francesco Montorsi and Alberto Briganti and Andrea Salonia and Patrizio Rigatti and Arthur Burnett",
year = "2006",
month = "6",
doi = "10.1016/j.eururo.2005.12.055",
language = "English (US)",
volume = "49",
pages = "979--986",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction?

AU - Montorsi, Francesco

AU - Briganti, Alberto

AU - Salonia, Andrea

AU - Rigatti, Patrizio

AU - Burnett, Arthur

PY - 2006/6

Y1 - 2006/6

N2 - Introduction and objectives: To systematically analyze and review the available evidence about the potential role of chronic administration of phosphodiesterase type 5 (PDE-5) inhibitors for the cure of erectile dysfunction (ED) based on clinical and basic science data. Methods: Analysis of published full-length papers that were identified with Medline and Cancerlit from January 1993 to September 2005. Abstracts published in the journals European Urology, the Journal of Urology, the International Journal of Impotence Research, and the Journal of Sexual Medicine as official proceedings of internationally known scientific societies held in the same time period were also assessed. Results: Chronic administration of PDE-5 inhibitors have reportedly been associated with increased persistent vascular and endothelial function-which represents a key factor in maintaining vascular tone and inducing vasodilation-by increasing the level of endothelial cGMP generated by activation of endothelial nitric oxide. Clinical studies have revealed a potential protective role of these compounds on endothelial function in short- and long-term assessments. Several studies based on animal models have provided direct experimental support for the role of PDE-5 inhibitors in improving the structure and function of the cavernosal tissue and have suggested potential molecular mechanisms involved. Conclusions: Although evidence increasingly supports the potential role of chronic administration of PDE-5 inhibitors for improving erectile function in patients affected by ED, long-term data are lacking. However, data available from animal models support the evidence of potential benefits induced on endothelial function by chronic exposure to PDE-5 inhibitors.

AB - Introduction and objectives: To systematically analyze and review the available evidence about the potential role of chronic administration of phosphodiesterase type 5 (PDE-5) inhibitors for the cure of erectile dysfunction (ED) based on clinical and basic science data. Methods: Analysis of published full-length papers that were identified with Medline and Cancerlit from January 1993 to September 2005. Abstracts published in the journals European Urology, the Journal of Urology, the International Journal of Impotence Research, and the Journal of Sexual Medicine as official proceedings of internationally known scientific societies held in the same time period were also assessed. Results: Chronic administration of PDE-5 inhibitors have reportedly been associated with increased persistent vascular and endothelial function-which represents a key factor in maintaining vascular tone and inducing vasodilation-by increasing the level of endothelial cGMP generated by activation of endothelial nitric oxide. Clinical studies have revealed a potential protective role of these compounds on endothelial function in short- and long-term assessments. Several studies based on animal models have provided direct experimental support for the role of PDE-5 inhibitors in improving the structure and function of the cavernosal tissue and have suggested potential molecular mechanisms involved. Conclusions: Although evidence increasingly supports the potential role of chronic administration of PDE-5 inhibitors for improving erectile function in patients affected by ED, long-term data are lacking. However, data available from animal models support the evidence of potential benefits induced on endothelial function by chronic exposure to PDE-5 inhibitors.

KW - Endothelial dysfunction

KW - Erectile dysfunction

KW - Phosphodiesterase type 5 inhibitors

KW - Radical prostatectomy

KW - Sildenafil

KW - Tadalafil

KW - Vardenafil

UR - http://www.scopus.com/inward/record.url?scp=33646364053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646364053&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2005.12.055

DO - 10.1016/j.eururo.2005.12.055

M3 - Article

C2 - 16431013

AN - SCOPUS:33646364053

VL - 49

SP - 979

EP - 986

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -